EU Positive Opinion on CYP-001 Paediatric Investigation Plan
Filed with ASX · · 2 pages · English
Summary by 6ix AI
The company plans to start with adults and subsequently conduct a pediatric trial after analyzing the adult trial results. The Positive Opinion will be forwarded to the European Commission for formal adoption, marking a significant step towards commercialization in Europe.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Cynata Therapeutics Limited on 6ix
Earlier from Cynata Therapeutics
- Cynata Secures Commitments for $1.5m Placement
- March 2026 Quarterly Activity Report & Appendix 4C
- Last Visit in GvHD Trial Completed
- Appendix 4D & Half-Year Financial Statements
- December 2025 Quarterly Activity Report and Appendix 4C
Later from Cynata Therapeutics
- Suspension from Quotation
- CYP-001 GvHD Trial Primary Evaluation Results
- Reinstatement to Official Quotation
- Board, Management Changes, Expenditure Reductions, RDTI Loan
- June 2026 Quarterly Activity Report & Appendix 4C
Follow Cynata Therapeutics into a list and get an email when it puts out news.
Follow Cynata Therapeutics